GABA in the deep layers of the superior Colliculus/Mesencephalic reticular formation mediates the enhancement of startle by the dopamine D1 receptor agonist SKF 82958 in rats.
GABA transmission in the deep layers of the superior colliculus/deep mesencephalic reticular formation (deep SC/Me) mediates several motor responses, including those expressed after systemic administration of dopamine agonists. In the present study we examined the role of the deep SC/Me in the modulation of the acoustic startle reflex and its enhancement by the dopamine D(1) agonist SKF 82958. Rats were implanted with bilateral cannulas into the deep SC/Me or superficial layers of the SC (super SC) and 1 week later were infused with various compounds. The GABA(A) antagonist bicuculline (0, 5, and 10 ng) produced a dose- and time-dependent enhancement of startle after infusion into the deep SC/Me, but not the super SC. Infusion of the GABA(A) agonist muscimol (0.1 microg) into the deep SC/Me, but not the super SC, blocked the enhancement of startle by systemic SKF 82958 (1 mg/kg) but had no effect on baseline startle by itself. This effect was not produced by infusion of the D(1) antagonist SCH 23390(1 microg) or the glutamate antagonist NBQX (0.1 microg). Deposits of FluoroGold into the deep SC/Me, combined with immunohistochemistry for glutamic acid decarboxylase (GAD), confirmed a direct GABAergic input from the substantia nigra pars reticulata (SNr) to the deep SC/Me. These results suggest that GABA tone in the deep SC/Me modulates the expression of startle as well as the enhancement of startle by dopamine D(1) agonists. On the basis of these data and previous work, we have proposed a striatonigral-tectal-reticular neural pathway mediating the effects of dopamine D(1) agonists on startle.
Meloni
E G
EG
The Interdepartmental Neuroscience Program and the Department of Psychiatry, Yale University School of Medicine and the Abraham Ribicoff Research Facilities of the Connecticut Mental Health Center, New Haven, Connecticut 06508, USA.
Davis
M
M
D000161:Acoustic Stimulation; D000704:Analysis of Variance; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D001640:Bicuculline / Q000494:pharmacology; D002404:Catheterization; D018491:Dopamine Agonists / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005456:Fluorescent Dyes; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D005968:Glutamate Decarboxylase / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D009118:Muscimol / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000819:agonists; D013216:Reflex, Startle / Q000187:drug effects*; D012154:Reticular Formation / Q000187:drug effects / Q000201:enzymology; D013266:Stilbamidines; D013477:Superior Colliculi / Q000187:drug effects* / Q000201:enzymology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
C049774:2-hydroxy-4,4'-diamidinostilbene, methanesulfonate salt; D001552:Benzazepines; D018491:Dopamine Agonists; D005456:Fluorescent Dyes; D018755:GABA Agonists; D018756:GABA Antagonists; D017447:Receptors, Dopamine D1; D013266:Stilbamidines; D009118:Muscimol; D005680:gamma-Aminobutyric Acid; C071262:SK&F 82958; D005968:Glutamate Decarboxylase; D001640:Bicuculline